Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

Journal of Immunology

Volumn 174, Issue 11, 2005, Pages 7179-7185

  Sumida, Shawm M ^a   Truitt, Diana M ^a   Lemckert, Angelique A C ^b   Vogels, Ronald ^b   Custers, Jerome H H V ^b   Addo, Marylyn M ^c   Lockman, Shahin ^d   Peter, Trevor ^d   Peyerl, Fred W ^a   Kishko, Michael G ^a   Jackson, Shawm S ^a   Gorgone, Darci A ^a   Lifton, Michelle A ^a   Essex, Myron ^d   Walker, Bruce D ^c   Goudsmit, Jaap ^b   Havenga, Menzo J E ^b   Barouch, Dan H ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CRUCELL HOLLAND BV   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEXON PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; DEVELOPING COUNTRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS;

EID: 21044439669     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.11.7179     Document Type: Article

References (33)

1. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
2. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
3. Sullivan, N. J., T. W. Geisbert, J. B., Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
4. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20: 73-79.
5. Nabel, G. J. 2001. Challenges and opportunities for development of an AIDS vaccine. Nature 410: 1002-1007.
6. Shiver, J. W., and E. A. Emini. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55: 355-372.
7. Barouch, D. H., P. F. McKay, S. M. Sumida, S. Santra, S. S. Jackson, D. A. Gorgone, M. A. Lifton, B. K. Chakrabarti, L. Xu, G. J. Nabel, and N. L. Letvin. 2003. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting HIV-1 vaccines. J. Virol. 77: 8729-8735.
8. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172: 6290-6297.
9. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78: 2666-2673.
10. Yang, Z. Y., L. S. Wyatt, W. P. Kong, Z. Moodie, B. Moss, and G. J. Nabel. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol 77: 799-803.
11. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77: 6305-6313.
12. Shiver, J. W. 2004. Development of an HIV-1 vaccine based on replication-defective adenovirus. In Keystone Symposium on HIV Vaccine Development: Progress and Prospects, April 2004. Whistler, British Columbia, Canada.
13. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. de Bethune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell interaction and bypass of preexisting adenovirus immunity. J. Virol. 77: 8263-8271.
14. Farina, S. F., G. P. Gao, Z. Q. Xiang, J. J. Rux, R. M. Burnett, M. R. Alvira, J. Marsh, H. C. Ertl, and J. M. Wilson. 2001. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75: 11603-11613.
15. Fitzgerald, J. C., G. P. Gao, A. Reyes-Sandoval, G. N. Pavlakis, Z. Q. Xiang, A. P. Wlazlo, W. Giles-Davis, J. M. Wilson, and H. C. Ertl. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170: 1416-1422.
16. + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171: 6774-6779.
17. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76: 2667-2675.
18. Toogood, C. I., J. Crompton, and R. T. Hay. 1992. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 73: 1429-1435.
19. Wohlfart, C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62: 2321-2328.
20. Gall, J. G., R. G. Crystal, and E. Falck-Pedersen. 1998. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72: 10260-10264.
21. Roy, S., P. S. Shirley, A. McClelland, and M. Kaleko. 1998. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72: 6875-6879.
22. Youil, R., T. J. Toner, Q. Su, M. Chen, A. Tang, A. J. Bett, and D. Casimiro. 2002. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13: 311-320.
23. Hong, S. S., N. A. Habib, L. Franqueville, S. Jensen, and P. A. Boulanger. 2003. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Add11520) for treatment of liver tumors. J. Virol. 77: 10366-10375.
24. Gahery-Segard, H., F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J. G. Guillet. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72: 2388-2397.
25. Sprangers, M. C., W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. Havenga, and S. Kostense. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41: 5046-5052.
26. Takahashi, H., Y. Nakagawa, C. D. Pendleton, R. A. Houghten, K. Yokomuro, R. N. Germain, and J. A. Berzofsky. 1992. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 255: 333-336.
27. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. [Published erratum appears in 1998 Science 280: 1821.] Science 274: 94-96.
28. + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. 168: 562-568.
29. Kostense, S., W. Koudstaal, M. Sprangers, G. J. Weverling, G. Penders, N. Helmus, R. Vogels, M. Bakker, B. Berkhout, M. Havenga, and J. Goudsmit. 2004. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18: 1213-1216.
30. Havenga, M. J., A. A. Lemckert, O. J. Ophorst, M. van Meijer, W. T. Germeraad, J. Grimbergen, M. A. van Den Doel, R. Vogels, J. van Deutekom, A. A. Janson, et al. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76: 4612-4620.
31. Rea, D., M. J. Havenga, M. van Den Assem, R. P. Sutmuller, A. Lemckert, R. C. Hoeben, A. Bout, C. J. Melief, and R. Offringa. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166: 5236-5244.
32. Crawford-Miksza, L., and D. P. Schnurr. 1996. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70: 1836-1844.
33. Ophorst, O. J., S. Kostense, J. Goudsmit, R. L. De Swart, S. Verhaagh, A. Zakhartchouk, M. Van Meijer, M. Sprangers, G. Van Amerongen, S. Yuksel, et al. 2004. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22: 3035-3044.